Filing Flows › 8-K events › Harmony Biosciences Holdings
Harmony Biosciences Holdings: departure or appointment of directors and officers
Form 8-K/A filed Oct 30, 2026 · items 5.02
What the filing says
Separation and Consulting Agreement with Jeffrey M. Dayno’s departure, on October 29, 2026, the Company, Harmony Biosciences, LLC and Harmony Biosciences Management, Inc. (“Harmony Management”) entered into a Separation and Consulting Agreement with Dr.
Read the filing on SEC EDGAR →
What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Every item ranked →
What this kind of filing means
Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.
Harmony Biosciences Holdings at a glance
Harmony Biosciences Holdings, Q3 2026: revenue $269M (+12% year over year), operating margin 20.2%. The chart follows the revenue to costs, profit and cash.
Harmony Biosciences Holdings: every quarter, Q/Q and Y/Y, holders and guidance →
Harmony Biosciences Holdings’s other material 8-Ks
- Nov 4, 2026 — FDA decisions Harmony Biosciences Reports Q3 Financial Results
Other recent ceo changes
- CapForce Nov 6, 2026
- Federal Home Loan Bank of New York Nov 6, 2026
- Tri-State Generation & Transmission Association Nov 6, 2026
- GeoVax Labs Nov 6, 2026
- RPM International Nov 6, 2026
- Fox Nov 6, 2026
- Enbridge Nov 6, 2026
- Federal Home Loan Bank of Des Moines Nov 5, 2026
- 1stdibs.com Nov 5, 2026
- TheRealReal Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.